Contact Us
Drug Search Results
More Filters [+]

CKD-396

Alternative Names: ckd-396, ckd 396, ckd396
Latest Update: 2020-02-05
Latest Update Note: Clinical Trial Update

Product Description

CKD-396 is being developed by Chong Kun Dang for the treatment of patients with Type2 Diabetes Mellitus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04246190?term=CKD-396&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CKD-396

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
A65_03BE1921

P1

Unknown status

Type 2 Diabetes

2020-04-10

59%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions